[{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Minerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Minerva Biotechnologies
huMNC2-CAR22 bears the “1XX” mutations in the T cell’s CD3-z signaling domain, targeting MUC1*, the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.
Minerva Biotechnologies has licensed from Memorial Sloan Kettering Cancer Center (MSK) “1XX” technology for use with Minerva’s proprietary anti-MUC1* antibodies to increase CAR T cell persistence in patients.